Objective. To describe ultrasound characteristics of adnexal malignancies, i.e., borderline ovarian tumors, primary invasive ovarian epithelial cancer stage 1, primary invasive ovarian epithelial cancer stage 2 -4, rare types of malignancy, and metastatic tumors.
Introduction
To plan optimal treatment of adnexal tumors it is important to be able to correctly discriminate between benign and malignant lesions. Ultrasound examination is a relatively simple and cheap diagnostic method, and an experienced ultrasound examiner can often confidently and correctly distinguish between benign and malignant pelvic masses on the basis of subjective evaluation of gray scale and color Doppler ultrasound findings [1, 2, 3] . The reported sensitivity and specificity with regard to malignancy of subjective evaluation in the studies cited were 88% and 96% 1 , and 96% and 90% 2 , and the reported sensitivity and specificity with regard to endometrioma were 92% and 97%, with regard to dermoid cyst 90% and 98%, and with regard to hydrosalpinx 100% and 100% 3 . For optimal planning of treatment it would be clinically useful to be able to distinguish not only between benignity and malignancy or between different types of benign pathology but also between different types of malignancy, for instance between ovarian borderline tumors, early and advanced ovarian cancer, and pelvic metastases.
The aim of this study was to describe clinical characteristics and ultrasound characteristics of different types of adnexal malignancies, i.e., borderline ovarian tumors, primary invasive epithelial ovarian cancer stage 1, primary invasive epithelial ovarian cancer stage 2 -4, rare types of pelvic malignancy, and metastatic tumors in the pelvis.
Patients and methods
The patients included in this study are a subgroup of the 1066 patients included in the International Ovarian Tumor Analysis (IOTA ) study, i.e., those 266 patients who had a pelvic mass that was suspected both clinically and at ultrasound examination to be of adnexal origin and was then histologically proven to be malignant. A short description of the IOTA study is given below. Details are given in a previous publication [4] .
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The IOTA study is a prospective international multicenter study including nine European ultrasound centers. The ethical committee at each participating center approved the study.
Recruitment was from June 1999 to June 2002. Patients presenting with at least one adnexal mass and who underwent ultrasound examination by a principal investigator at one of the centers were eligible for inclusion. Informed consent was obtained from every woman participating in the study. A history following a standardized protocol was taken from each patient. A woman was considered to be postmenopausal, if she reported a period of at least 12 months of amenorrhea after the age of 40 years, provided that medication or disease did not explain the amenorrhea.
Women 50 years or older who had undergone hysterectomy were also defined as postmenopausal. Blood samples were drawn for analysis of CA 125, but the availability of this biochemical end-point was not a requirement for inclusion. CA 125 results were unavailable to the ultrasound examiner at the time of the ultrasound examination. A transvaginal gray scale and color Doppler ultrasound examination using a high-end ultrasound system equipped with a transvaginal transducer with a frequency of 4 -8 MHz was performed in all cases.
Transabdominal sonography was added, if a large mass could not be seen in its entirety using a transvaginal probe. A standardized examination technique and standardized definitions of ultrasound terms were used in all centers. The standardized terms and definitions have been published [5] . A papillary projection was defined as any solid protrusion into a cyst cavity from the cyst wall with a height greater than or equal to 3 mm [5] . In case of more than one pelvic mass, data from the mass with the most complex ultrasound morphology were used. Exclusion criteria were: pregnant patient, inability to tolerate transvaginal sonography, surgery >120 days after sonographic assessment, disagreement in the classification (malignant or benign) between the original pathology report and the report of an external expert reviewer, or incomplete 6 submission of data. Data were submitted via the internet to a central database using a dedicated, secure data collection system developed for the study [6] .
Statistical analysis
Statistical analysis was carried out by the statistician of our team (LA) using the SAS System Within categorical variables with many categories (e.g., echogenicity of cyst fluid, type of tumor, color score) permutation methods were used, because in these cases Bonferroni´s correction would have been too conservative. In these cases, too, a p-value of < 0.0167 was considered statistically significant.
Multivariable logistic regression with stepwise selection of variables was used in the group of borderline tumors and stage 1 primary invasive epithelial cancers (n = 97) to determine which clinical variables and which ultrasound features were independently associated with invasiveness, a p-value <0.05 being the threshold for including a variable in the model.
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The funding bodies had no role in the design of the study, the analysis, the interpretation of results, the drafting of the report, or the decision to submit the paper for publication.
Results
There Table 1 .
Clinical information including CA125 values for the five groups of tumor are shown in Table   2 . Ultrasound findings are shown in Table 3 . The metastatic tumors tended to be small, solid, and well vascularized. The rare malignancies tended to be large, solid, and well vascularized. carcinomas that develop in a stepwise manner from well-recognized precursors, i.e., borderline tumors. They are slow-growing as evidenced by them being large and often confined to the ovary at diagnosis [7] . In contrast, type II tumors are high-grade at presentation and are rarely associated with morphologically recognizable precursor lesions. They are suggested to develop de novo from the surface epithelium of the ovary, evolve rapidly, metastasize early in their course, and to be highly aggressive [7] . There are also several distinct molecular features that distinguish type I and type II tumors [7] . The two pathways suggested by Shih and Kurman were described for serous tumors and then extrapolated to other types of tumor, i.e., mucinous carcinoma, endometrioid carcinoma, malignant Brenner tumor, and clear cell carcinoma. The dualistic model proposed by Shih and Kurman [7] is indirectly supported not only by our findings but also by those of a Japanese study [8] : in 54% (19/35) of patients with ovarian carcinomas a cyst was detected at ultrasound examination 2 -12 months before surgery, all these cancers being well differentiated stage 1 cancers; in the remaining 46% (16/35) of ovarian carcinomas, ultrasound examinations performed 2 -12 months before surgery had been normal, and 89% (8/9) of the serous tumors in this group were stage 3, grade 2 or 3.
To sum up, the possibility to discriminate preoperatively between ovarian borderline tumors, early and advanced ovarian cancer, and pelvic metastases may improve the possibility to provide optimal management. We have shown that different types of extrauterine pelvic malignancy manifest different characteristics at transvaginal ultrasound examination. The use of these ultrasound characteristics to predict the type of malignancy needs to be tested prospectively. 
